Navigation Links
Gen-Probe to Consolidate Industrial Assets Into New, Independent Company
Date:9/14/2009

SAN DIEGO, Sept. 14 /PRNewswire-FirstCall/ -- Gen-Probe Incorporated (Nasdaq: GPRO) announced today that it is spinning off its industrial testing assets into a new, independent company focused on developing rapid, highly accurate molecular assays for biopharmaceutical production, water and food safety testing, and other applications.

Gen-Probe initially will own 19.9% of the new company, Roka Bioscience, Inc. Affiliates of leading private equity firms OrbiMed Advisors, TPG (TPG Biotechnology) and New Enterprise Associates have agreed to provide Roka up to $37.2 million in aggregate equity funding to complete development of several industrial assays and Gen-Probe's Closed Unit Dose Assay (CUDA) system, a fully integrated, portable testing instrument that can deliver highly accurate molecular results in approximately one hour.

"We believe establishing a highly focused, standalone company is the best way to maximize the considerable long-term potential of our molecular technologies in industrial markets," said Carl Hull, Gen-Probe's president and chief executive officer (CEO). "Our ownership position enables us to participate in Roka's long-term success, while allowing us to concentrate Gen-Probe's internal resources and core competencies on clinical opportunities in infectious disease testing, blood screening, transplant diagnostics and oncology."

Eighteen former Gen-Probe employees with expertise in industrial fields have joined Roka, which will begin operating as an independent company immediately. Gen-Probe also will contribute to Roka its CUDA system, other industrial assets, and the right to use certain of its technologies and related know-how in industrial markets. In addition to biopharmaceutical production and water and food safety testing, these markets include veterinary, environmental and bioterrorism testing. Roka also will have rights to develop certain infection control tests for use on the CUDA system.

Gen-Probe will receive royalties on any potential Roka product sales, and retain rights to use the CUDA system for clinical applications. In addition, Gen-Probe will provide contract manufacturing and certain other services to Roka on a transitional basis.

The spin-off is expected to have no material effect on Gen-Probe's 2009 earnings, as reductions in operating expenses will be offset by lower collaborative research and product revenues.

Gen-Probe's industrial testing collaborators, Millipore and GE Water (a division of GE Energy, a business unit of General Electric), have agreed to the transfer of their respective collaborations with Gen-Probe to Roka. Gen-Probe's collaboration with Millipore is focused on developing microbial detection assays to ensure the purity of biopharmaceutical production processes, while the Company is working with GE to develop rapid molecular tests to detect microbial contamination in industrial water.

Roka's CEO is Paul G. Thomas, an experienced healthcare executive who recently was chairman, president and CEO of LifeCell Corporation, a regenerative medicine company, before it was sold to Kinetic Concepts, Inc., for $1.8 billion in 2008. During his tenure at LifeCell, annual product revenues increased from $7.2 million in 1998, to $190 million in 2007.

"I am excited to have the opportunity to lead a talented group of scientists and engineers who are striving to revolutionize industrial testing markets with high-performance molecular assays and systems," Mr. Thomas said. "We will pursue our shared vision based on a robust technology platform, two top-notch commercial partners, and strong financial backing."

About Gen-Probe

Gen-Probe Incorporated is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective nucleic acid tests (NATs) that are used primarily to diagnose human diseases and screen donated human blood. Gen-Probe has more than 25 years of NAT expertise, and received the 2004 National Medal of Technology, America's highest honor for technological innovation, for developing NAT assays for blood screening. Gen-Probe is headquartered in San Diego and employs approximately 1,200 people. For more information, go to www.gen-probe.com.

Caution Regarding Forward-Looking Statements

Any statements in this press release about Gen-Probe's expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as believe, will, expect, anticipate, estimate, intend, plan and would. For example, statements concerning new industrial products, customer adoption of these products, and results of future R&D studies are all forward-looking statements. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections contained in the forward-looking statements include but are not limited to: (i) the risk that Roka's development of industrial assays and platforms, including the CUDA system, will not be successful; (ii) the risk that these or other new products will not be adopted by customers; (iii) the possibility that the value of Gen-Probe's investment in Roka will decline, potentially resulting in a charge to the Company's earnings; (iv) the risk that Roka and its partners may not be able to compete effectively; (v) the risk that Roka may not be able to maintain its current corporate collaborations and enter into new corporate collaborations or customer contracts; and (vi) the risk that third parties may not distribute Roka's products effectively. The foregoing describes some, but not all, of the factors that could affect our ability to achieve results described in any forward-looking statements. For additional information about risks and uncertainties Gen-Probe faces and a discussion of the Company's financial statements and footnotes, see documents filed with the SEC, including the most recent annual report on Form 10-K and all subsequent periodic reports. We assume no obligation and expressly disclaim any duty to update any forward-looking statement to reflect events or circumstances after the date of this news release or to reflect the occurrence of subsequent events.

    Contact:
    Michael Watts
    Vice president, investor relations and
    corporate communications
    858-410-8673


'/>"/>
SOURCE Gen-Probe Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Gen-Probe to Webcast Presentation at Bank of Americas 37th Annual Investment Conference
2. Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues
3. Gen-Probe to Webcast Three Upcoming Presentations
4. Gen-Probe Announces Webcast of Fourth Quarter and Full Year 2007 Earnings Conference Call
5. Carl Hull Named President and Chief Operating Officer of Gen-Probe
6. Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007
7. Gen-Probe to Webcast Presentations at Lehman and Cowen Healthcare Conferences
8. Gen-Probe to Webcast Presentation at Morgan Stanley Global Healthcare Unplugged Conference
9. Gen-Probe Reports Strong Financial Results for First Quarter 2008, Raises Full-Year Guidance
10. Gen-Probe to Webcast Presentation at Deutsche Bank 33rd Annual Health Care Conference
11. Lucy Shapiro, Ph.D., Elected to Gen-Probe Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... 2016  Wellcentive today announced it has been ... -based community care organization (CCO) with more ... quality reporting and care management solutions and services. ... of quality managers, analysts and care managers while ... serving FamilyCare members. Oregon ...
(Date:2/11/2016)... 2016   BioInformant announces the February 2016 ... Products, Opportunities, Tools, and Technologies – Market Size, Segments, ... The first and only ... industry, BioInformant has more than a decade of historical ... by stem cell type. This powerful 175 page global ...
(Date:2/10/2016)... , Febr. 10, 2016 /PRNewswire/ - BioAmber Inc. (NYSE: ... to announce that Mitsui & Co. Ltd., its partner ... acid plant, is investing an additional CDN$25 million in ... its stake from 30% to 40%.  Mitsui will also ... acid produced in Sarnia , providing ...
(Date:2/10/2016)... -- ASAE is introducing a hybrid membership model which ... option of joining or renewing through an organizational purchasing ... size, every employee in any size association or AMC ... available member benefits.   John H. Graham, ... will allow organizations of any size and their employees ...
Breaking Biology Technology:
(Date:2/2/2016)... 2, 2016 This BCC Research report ... by reviewing the recent advances in high throughput ... the field forward. Includes forecast through 2019. ... challenges and opportunities that exist in the bioinformatic ... developers, as well as IT and bioinformatics service ...
(Date:2/2/2016)... , Feb. 2, 2016  Based on its ... & Sullivan recognizes US-based Intelligent Retinal Imaging Systems ... Sullivan Award for New Product Innovation. IRIS, a ... North America , is poised to ... growing diabetic retinopathy market. The IRIS technology presents ...
(Date:1/28/2016)... Jan. 28, 2016 Synaptics (NASDAQ: SYNA ), a ... its second quarter ended December 31, 2015. ... of fiscal 2016 increased 2 percent compared to the comparable quarter ... of fiscal 2016 was $35.0 million, or $0.93 per diluted share. ... income for the first quarter of fiscal 2016 grew 9 percent ...
Breaking Biology News(10 mins):